Abstract: SA-PO862

Change in EXTL2, a Novel Factor Related to Vascular Calcification, in Hemodialysis Patients

Session Information

  • Vascular Calcification
    November 04, 2017 | Location: Hall H, Morial Convention Center
    Abstract Time: 10:00 AM - 10:00 AM

Category: Mineral Disease

  • 1205 Vascular Calcification

Authors

  • Goto, Shunsuke, Kobe University Graduate School of Medicine, Kobe, Japan
  • Nishi, Shinichi, Kobe University Graduate School of Medicine, Kobe, Japan
  • Fujii, Hideki, Kobe University Graduate School of Medicine, Kobe, Japan
  • Nadanaka, Satomi, Kobe Pharmaceutical University, Kobe, Japan
  • Watanabe, Kentaro, Kobe University Graduate School of Medicine, Kobe, Japan
  • Watanabe, Shuhei, Kobe University Graduate School of Medicine, Kobe, Japan
  • Kono, Keiji, Kobe University Graduate School of Medicine, Kobe, Japan
  • Nakanishi, Shohei, Chibune General Hospital, Osaka, Japan
  • Kim, Jong-Il, Chibune General Hospital, Osaka, Japan
  • Kitagawa, Hiroshi, Kobe Pharmaceutical University, Kobe, Japan
Background

Vascular calcification is an important risk factor in hemodialysis patients. Although various factors are associated with vascular calcification, the mechanisms are not fully understood. Recent experimental study has reported that knockout of glycosaminoglycan-related enzyme exostosin-like 2 (EXTL2) was associated with vascular calcification in 5/6 nephrectomized mice. However, there are only a few clinical papers on it and EXTL2 has not been investigated in hemodialysis patients yet. The aim of our study was to investigate EXTL2 in hemodialysis patients.

Methods

We included 15 stable hemodialysis patients and 12 healthy control subjects in this study. We measured mRNA expressions of EXTL2, other glycosaminoglycan-related enzyme chondroitin 4-O-sulfotransferase 1 (C4ST1), xylosyltransferase 2 (XYLT2), and family with sequence similarity 20 member B (Fam20B) in blood. These mRNAs expressions were compared between hemodialysis patients and controls.

Results

mRNA expression levels of EXTL2 were 0.15 (0.10-0.24) in hemodialysis patients, and those were significantly lower compared to the control subjects (0.45 (0.27-0.55), p < 0.05), while, mRNA expression levels of C4ST1, XYTL2, and Fam20B were comparable between the two groups.

Conclusion

Our data suggested that EXTL2 levels decreased in hemodialysis patient compared to general population. Further study is needed to elucidate whether the decrease in EXTL2 is associated with the progression of vascular calcification in hemodialysis patients.

Funding

  • Private Foundation Support